The mechanism and research progress of GM-CSF protein in cytokine storm

1. Mechanisms and Research Background of Cytokine Storm

SARS-CoV-2 infection typically causes lymphopenia and inflammatory cytokine release, with cytokine storm being considered one of the major reasons for disease progression in severe cases. During CAR-T cell therapy, T cell activation similarly releases large amounts of inflammatory cytokines, triggering cytokine release syndrome (CRS), where IL-6 plays a key role, forming the conventional strategy of using IL-6 monoclonal antibodies to address CRS. Although the cytokine storm triggered by SARS-CoV-2 differs in etiology from CRS induced by CAR-T therapy, they share similarities in clinical manifestations and pathogenic mechanisms. Clinical studies show that levels of inflammatory cytokines such as IL-6, IL-10, and TNF-α are significantly elevated in severe COVID-19 patients, suggesting their involvement in disease progression.

2. The Critical Role of GM-CSF Protein in Cytokine Storm

Researchers from the Chinese Academy of Sciences analyzed the immune characteristics of SARS-CoV-2-infected patients and found that GM-CSF protein levels were significantly elevated in severe cases, showing stronger correlation than IL-6. The study revealed that GM-CSF-positive CD8+ T cells were significantly associated with ICU admission, while IL-6 and TNF-α did not show such correlation. Additionally, GM-CSF-positive CD4+ T cells and GM-CSF-induced CD14+CD16+ monocytes were also closely linked to ICU admission. These findings suggest that GM-CSF protein may play a more critical role in severe COVID-19 patients, providing a new target for cytokine storm intervention.

3. Structure and Signal Transduction Mechanism of GM-CSF Protein

GM-CSF protein is a secreted cytokine expressed in various immune cells, including granulocytes, dendritic cells, T cells, and B cells. Its receptor consists of two subunits: an α chain and a β chain, with the β chain being shared by GM-CSF, IL-3, and IL-5. Upon binding to its receptor, GM-CSF forms hexameric and dodecameric complexes, activating downstream signaling pathways such as JAK-STAT, PI3K, and NFκB. These pathways mediate the broad biological functions of GM-CSF in cell survival, proliferation, differentiation, and inflammatory responses. Its role in inflammatory diseases provides a molecular basis for targeted intervention.

4. Mechanistic Differences Between Targeting GM-CSF and Targeting IL-6

Mechanistically, blocking GM-CSF protein can inhibit granulocyte activation and reduce the production of multiple downstream cytokines. In contrast, blocking IL-6 primarily reduces IL-6 itself, with limited effects on granulocyte activation and downstream cytokine production. Cytokine storm involves various cytokines and chemokines such as MCP-1, MIP1a, MIG, IP10, and IL-1. Blocking GM-CSF can simultaneously suppress the production of these factors, offering broader control over inflammatory responses. In clinical practice, IL-6 monoclonal antibodies show limited efficacy in alleviating cytokine-related neurotoxicity during CAR-T-induced CRS, suggesting that targeting a single inflammatory factor may have limitations. This further supports the research value of GM-CSF as a target for cytokine storm intervention.

5. Research Value of GM-CSF in Inflammatory Diseases

GM-CSF protein plays an important role in various inflammatory diseases, and intervention strategies targeting this protein have entered clinical research stages for autoimmune diseases such as rheumatoid arthritis. In CAR-T therapy, studies on GM-CSF antibodies demonstrate that such interventions can enhance CAR-T antitumor effects while reducing levels of chemokines (e.g., MCP-1, IP-10) and cytokines (e.g., IL-6, IL-1), lowering neurotoxicity incidence without introducing new safety risks. These findings provide a preliminary foundation for the application of GM-CSF-targeted strategies in cytokine storm intervention.

6. Application Prospects of GM-CSF-Targeted Strategies

Given the critical role of GM-CSF protein in the immune characteristics of severe infection patients, clinical research on intervention strategies targeting this protein is underway. GM-CSF antibody drugs developed by various research institutions have completed early clinical studies for indications such as rheumatoid arthritis and are planned to expand to cytokine storm-related indications. These drugs neutralize GM-CSF protein, blocking granulocyte activation and downstream cytokine cascades to control excessive immune responses. Compared to single-target interventions, GM-CSF-targeted strategies may offer broader inflammatory control. As understanding of the immunopathological mechanisms of SARS-CoV-2 infection deepens, research on GM-CSF as a key target for cytokine storm will continue to advance.

7. Which Manufacturers Provide GM-CSF Protein?

Nanjing UA-Biotech Co., Ltd. (UA-Bio) has independently developed "GM-CSF Protein, Human", a high-quality recombinant protein reagent specifically designed for immune cell culture, dendritic cell differentiation, and tumor immunology research. This protein is human granulocyte-macrophage colony-stimulating factor (GM-CSF), which efficiently activates GM-CSF receptor signaling pathways, promoting the proliferation and differentiation of granulocytes, macrophages, and dendritic cells. It provides a stable and reliable standardized tool for research in hematopoietic development, cell therapy, and vaccine development.

Nanjing UA-Biotech Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding "GM-CSF Protein, Human" (Product No.: UA040002), please feel free to contact us.